C.R. Bard Acquires NeoMend for $165,000,000

  • Feed Type
  • Date
  • Company Name
  • Mailing Address
    60 Technology Drive Irvine, CA 92618
  • Company Description
    NeoMend, Inc. is a privately held, clinical stage biomedical device company engaged in the development and commercialization of advanced surgical wound healing products.
  • Website
  • Transaction Type
  • Transaction Amount
  • Transaction Round
  • Proceeds Purposes
  • M&A Terms
    The merger consideration is for a purchase price of $140 million paid at closing and future contingent payments up to an additional $25 million based on specific revenue-based milestones through 2016.